Study of Reduced Toxicity Myeloablative Conditioning Regimen for Cord Blood Transplantation in Pediatric AML
Status:
Unknown status
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
Cord blood transplantation (CBT) is an alternative option for patients with pediatric acute
leukemia that indicated stem cell transplantation. Although CBT is as affective as unrelated
bone marrow transplantation with lower graft versus host disease (GVHD) severity and
incidence, transplantation related mortality (TRM) has been major problems after
myeloablative conditioning. To reduce TRM, CBT with non-myeloablative conditionings have been
performed but not so satisfactory especially for engraftment rate. Recently reduced toxicity
myeloablative conditioning regimen was developed with promising result in adult bone marrow
or mobilized peripheral blood transplantation. To increase the engraftment potential with low
TRM rate, reduced toxicity myeloablative conditioning composed of fludarabine, intravenous
busulfan plus thymoglobulin is planned for pediatric patients with acute myeloid leukemia.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
The Korean Society of Pediatric Hematology Oncology